<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02528331</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00047168</org_study_id>
    <nct_id>NCT02528331</nct_id>
  </id_info>
  <brief_title>Cognitive Behavioral Strategies and Transcranial Magnetic Stimulation in Obsessive-Compulsive Disorder: Open Label Study</brief_title>
  <acronym>CBT-TMS</acronym>
  <official_title>Cognitive Behavioral Strategies and Transcranial Magnetic Stimulation in Obsessive-Compulsive Disorder: Open Label Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of repetitive TMS (rTMS) delivered
      simultaneously with elements of cognitive behavioral therapy/exposure-response prevention
      (CBT/ERP) in adult subjects (greater or equal to 18 years old) with obsessive-compulsive
      disorder (OCD). This is an open label study that involves standard of care for OCD (CBT) and
      an investigational treatment modality (TMS). The investigators will compare the Yale-Brown
      Obsessive Compulsive Scale (YBOCS) scores before and after treatment to quantify clinical
      improvement. The side effects from TMS include, but are not limited to, headache, seizure,
      and general pain. CBT has minimal side effects other than mental discomfort during the
      exposure sessions. For safety concerns, pregnant women and subjects with seizure-related
      history will be excluded as well as other indicated conditions in the details protocol.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI has left Duke
  </why_stopped>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission Rate, as Measured by Y-BOCS</measure>
    <time_frame>6 weeks</time_frame>
    <description>Remission is defined as end-point Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score less than the value of 16.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response, as Measured by Y-BOCS</measure>
    <time_frame>6 weeks</time_frame>
    <description>Complete response is defined as a reduction of Y-BOCS score greater than 35%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial Response Rate, as Measured by Y-BOCS</measure>
    <time_frame>6 weeks</time_frame>
    <description>Partial response is defined as a reduction of greater than 25%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Adverse Events</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Obsessive Compulsive Disorder (OCD)</condition>
  <arm_group>
    <arm_group_label>rTMS and Cognitive Behavior Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial magnetic stimulation</intervention_name>
    <arm_group_label>rTMS and Cognitive Behavior Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive behavioral therapy</intervention_name>
    <arm_group_label>rTMS and Cognitive Behavior Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Subjects must meet all of the following inclusion criteria to qualify for enrollment into
        the study:

          1. All subjects will be 18 - 65 years of age.

          2. Obsessive-compulsive disorder:

               -  Subjects will meet the DSM-IV primary diagnosis of obsessive-compulsive

               -  Y-BOCS total score &gt; 16

          3. Subjects are willing and able to adhere to the intensive treatment schedule and all
             required study visits.

        Exclusion Criteria

        Subjects will be excluded from study participation if one of the following exclusion
        criteria applies:

          1. Subjects are unable or unwilling to give informed consent.

          2. No exclusion criteria for comorbid DSM diagnosis.

          3. Subjects with a clinically defined neurological disorder that caused significant
             safety concern to receive TMS treatment, including, but not limited to:

               -  Any condition likely to be associated with increased intracranial pressure.

               -  Space occupying brain lesion.

               -  Any history of seizure EXCEPT those therapeutically induced by ECT (childhood
                  febrile seizures are acceptable and these subjects may be included in the study).

               -  History of stroke.

               -  Transient ischemic attack within two years.

               -  Cerebral aneurysm.

               -  Dementia.

               -  Mini Mental Status Exam (MMSE-2) score of &lt;24.

               -  Parkinson's disease.

               -  Huntington's disease.

               -  Multiple sclerosis.

               -  Increased risk of seizure for any reason, including prior diagnosis of increased
                  intracranial pressure (such as after large infarctions or trauma), or currently
                  taking medication that lowers the seizure threshold. Medications that lower the
                  seizure threshold are included in the Prohibited Concomitant Medication (Section
                  5.8).

          4. Subjects with any of the following treatment histories:

               -  TMS treatment within 6 months prior to the screening visit.

               -  Lifetime history of treatment with Deep Brain Stimulation

               -  Use of any investigational drug or device within 4 weeks of the randomization
                  visit.

               -  If participating in psychotherapy, must have been in stable treatment for at
                  least 2 months prior to entry into the study, with no anticipation of change in
                  the frequency of therapeutic sessions, or the therapeutic focus over the duration
                  of the trial.

               -  Recent 2-month medication changes

          5. Contraindication to receive TMS:

               -  Cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute,
                  unstable cardiac disease.

               -  Intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear
                  implants, stents, or electrodes) or any other metal object within or near the
                  head, excluding the mouth, which cannot be safely removed.

               -  Clinically significant abnormality or clinically significant unstable medical
                  condition, as indicated by medical history, physical examination, ECG results, or
                  clinical laboratory testing, that in the Investigator's judgment might pose a
                  potential safety risk to the subject or limit interpretation of the trial
                  results, e.g., any uncontrolled thyroid disorders, hepatic, cardiac, pulmonary
                  and renal malfunctioning.

          6. Women who are currently pregnant or not using a medically acceptable means of birth
             control and women who are breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Weiner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2015</study_first_submitted>
  <study_first_submitted_qc>August 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2015</study_first_posted>
  <results_first_submitted>November 29, 2016</results_first_submitted>
  <results_first_submitted_qc>December 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 9, 2017</results_first_posted>
  <last_update_submitted>December 19, 2016</last_update_submitted>
  <last_update_submitted_qc>December 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transcranial magnetic stimulation (TMS)</keyword>
  <keyword>Cognitive behavioral therapy (CBT)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>rTMS and Cognitive Behavior Therapy</title>
          <description>Transcranial magnetic stimulation
Cognitive behavioral therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>rTMS and Cognitive Behavior Therapy</title>
          <description>Transcranial magnetic stimulation
Cognitive behavioral therapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.5" lower_limit="48" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Remission Rate, as Measured by Y-BOCS</title>
        <description>Remission is defined as end-point Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score less than the value of 16.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rTMS and Cognitive Behavior Therapy</title>
            <description>Transcranial magnetic stimulation
Cognitive behavioral therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Remission Rate, as Measured by Y-BOCS</title>
          <description>Remission is defined as end-point Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score less than the value of 16.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Response, as Measured by Y-BOCS</title>
        <description>Complete response is defined as a reduction of Y-BOCS score greater than 35%.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rTMS and Cognitive Behavior Therapy</title>
            <description>Transcranial magnetic stimulation
Cognitive behavioral therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response, as Measured by Y-BOCS</title>
          <description>Complete response is defined as a reduction of Y-BOCS score greater than 35%.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Partial Response Rate, as Measured by Y-BOCS</title>
        <description>Partial response is defined as a reduction of greater than 25%.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rTMS and Cognitive Behavior Therapy</title>
            <description>Transcranial magnetic stimulation
Cognitive behavioral therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Partial Response Rate, as Measured by Y-BOCS</title>
          <description>Partial response is defined as a reduction of greater than 25%.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Adverse Events</title>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rTMS and Cognitive Behavior Therapy</title>
            <description>Transcranial magnetic stimulation
Cognitive behavioral therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Adverse Events</title>
          <units>percentage of adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>rTMS and Cognitive Behavior Therapy</title>
          <description>Transcranial magnetic stimulation
Cognitive behavioral therapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This trial was terminated early leading to small numbers of subjects analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Richard Weiner, MD, PhD</name_or_title>
      <organization>Duke University</organization>
      <phone>919-681-8742</phone>
      <email>weine002@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

